Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase II/III-study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

Trial Profile

A Multicenter Phase II/III-study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 25 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti HER2 small molecule imaging agent (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
  • Focus Diagnostic use
  • Acronyms Affibody-3

Most Recent Events

  • 24 Mar 2024 This trial has been Discontinued in Sweden (End date: 2024-02-05) according to European Clinical Trials Database record.
  • 01 Sep 2023 Results investigating how [68Ga]Ga-ABY-025 uptake corresponds to biopsy results and early treatment response in both primary breast cancer (PBC) planned for neoadjuvant chemotherapy and MBC, published in the Journal of Nuclear Medicine
  • 09 Dec 2021 According to an Affibody media release, data presented at the San Antonio Breast Cancer Symposium 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top